Prime Medicine, Inc.(PRME)
$3.89-0.41 (-9.53%)
PRME
Prime Medicine, Inc. financials statements
$3.89
At close:-0.41 (-9.53%)
Want to see PRME full AI Analyst Report?
Prime Medicine, Inc. (PRME) Ratios
937 Followers
Prime Medicine, Inc. Ratios
PRME's free cash flow for Q3 2026 was $-36.98M. For the 2026 fiscal year, PRME's free cash flow was decreased by $-298.00K and operating cash flow was $-36.68M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.84 | 5.58 | 2.53 | 11.10 | 4.67 |
| Quick Ratio | 4.84 | 5.58 | 2.53 | 11.10 | 4.67 |
| Cash Ratio | 1.68 | 4.81 | 0.74 | 7.02 | 3.20 |
| Solvency Ratio | -0.88 | -1.31 | -3.18 | -2.72 | -2.65 |
| Operating Cash Flow Ratio | -4.34 | -3.24 | -2.93 | -4.93 | -0.59 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -40.57M | $ 67.53M | $ 82.20M | $ 252.57M | $ 208.28M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.34 | 0.14 | 0.07 | 0.08 | 0.03 |
| Debt-to-Equity Ratio | 0.96 | 0.27 | 0.10 | 0.09 | 0.04 |
| Debt-to-Capital Ratio | 0.49 | 0.21 | 0.09 | 0.08 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.47 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.84 | 1.94 | 1.46 | 1.14 | 1.26 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.78 | 0.34 | 0.15 | 0.30 | 0.11 |
| Net Debt to EBITDA | -0.27 | 0.75 | 0.15 | 1.39 | 2.09 |
| Profitability Margins | |||||
| Gross Profit Margin | -58.05% | 100.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | -4342.44% | -6566.61% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | -4226.21% | -6361.18% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | -4498.06% | -6787.36% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | -4342.44% | -6566.61% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | -4342.44% | -6566.61% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -4342.44% | -6566.61% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 99.86% | 99.23% | 99.71% |
| EBT Per EBIT | 96.54% | 96.75% | 96.88% | 105.34% | 196.34% |
| Return on Assets (ROA) | -58.69% | -65.84% | -102.21% | -33.81% | -54.78% |
| Return on Equity (ROE) | -166.41% | -127.90% | -148.89% | -38.52% | -69.03% |
| Return on Capital Employed (ROCE) | -68.25% | -78.01% | -149.02% | -34.94% | -34.64% |
| Return on Invested Capital (ROIC) | -66.48% | -76.94% | -139.40% | -33.49% | -33.53% |
| Return on Tangible Assets | -58.69% | -65.84% | -102.21% | -33.81% | -54.78% |
| Earnings Yield | -38.97% | -56.56% | -24.58% | -6.74% | -11.24% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.82 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.03 | 0.04 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.03 | 0.02 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -443.08 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 443.08 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.09 | -1.04 | -1.82 | -1.36 | -0.36 |
| Free Cash Flow Per Share | -1.12 | -1.10 | -1.91 | -1.52 | -0.40 |
| Dividend Paid and CapEx Coverage Ratio | -35.88 | -16.84 | -18.96 | -8.19 | -8.21 |
| Capital Expenditure Coverage Ratio | -35.88 | -16.84 | -18.96 | -8.19 | -8.21 |
| Operating Cash Flow Coverage Ratio | -1.40 | -3.01 | -12.13 | -4.59 | -3.28 |
| Operating Cash Flow to Sales Ratio | -35.10 | -41.19 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -32.37% | -37.58% | -21.61% | -8.19% | -2.60% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.57 | -1.77 | -4.07 | -14.83 | -8.90 |
| Price-to-Sales (P/S) Ratio | 111.44 | 116.10 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 4.27 | 2.26 | 6.06 | 5.71 | 6.14 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.09 | -2.66 | -4.63 | -12.21 | -38.49 |
| Price-to-Operating Cash Flow Ratio | -3.18 | -2.82 | -4.87 | -13.70 | -43.17 |
| Price-to-Earnings Growth (PEG) Ratio | 0.14 | 0.07 | -0.08 | 0.62 | -0.00 |
| Enterprise Value Multiple | -2.91 | -1.08 | -4.17 | -14.41 | -15.45 |
| Enterprise Value | 569.59M | 204.63M | 778.05M | 1.65B | 1.30B |
| EV to EBITDA | -2.91 | -1.08 | -4.17 | -14.41 | -15.45 |
| EV to Sales | 122.97 | 68.60 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -3.41 | -1.57 | -4.47 | -11.14 | -33.91 |
| EV to Operating Cash Flow | -3.50 | -1.67 | -4.70 | -12.50 | -38.04 |
| Tangible Book Value Per Share | 0.81 | 1.29 | 1.46 | 3.25 | 2.50 |
| Shareholders’ Equity Per Share | 0.81 | 1.29 | 1.46 | 3.25 | 2.50 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Revenue Per Share | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.35 | -1.65 | -2.18 | -1.25 | -1.73 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 0.99 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.04 | 1.05 | 1.96 |
| Research & Development to Revenue | 34.68 | 52.06 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 11.30 | 16.82 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 6.32 | 8.74 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.81 | 0.63 | 0.83 | 1.08 | 0.21 |
Currency in USD
